Kit Check, a Washington, D.C.-based provider of hospital pharmacy kit processing and medication tracking software, raised $12m in Series B funding.
The round was led by Kaiser Permanente Ventures with participation from New Leaf Venture Partners, Sands Capital Ventures, Easton Capital Investment Group, LionBird, and Rex Health Ventures. In conjunction with the funding, Dave Schulte, vice president and senior managing director of Kaiser Permanente Ventures, will join Kit Check’s Board of Directors.
The company, which has raised $22.4m to date, intends to use the funds to further extend its product portfolio and customer growth.
Founded in 2012 by CEO Kevin MacDonald, Kit Check provides automated hospital pharmacy kit processing and medication tracking software to replace time consuming and error-prone manual processes in hospital medication handling. Products include: Kit Check for automated pharmacy kit medication restocking in hospital pharmacies and tracking throughout the hospital. Anesthesia Check for automated anesthesia medication tracking, validation and recording in the operating room to the syringe level.
The company serves approx. 145 hospital pharmacies throughout the United States.